The methods of assessment of quality and safety of medicaments on the basis of low molecular weight heparins

The methods of assessment of quality and safety of medicaments on the basis of low molecular weight heparins

To consider the methods for assessing quality and safety of drugs on the basis of low molecular weight heparin.

Bibliographic Details
Main Authors:	E. A. Arianova, M. N. Bogachuk, O. I. Perederyaev
Format:	Article
Language:	Russian
Published:	Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) 2022-12-01
Series:	Сеченовский вестник
Subjects:	heparin low molecular weight heparin low molecular weight heparin drugs high-performance liquid chromatography capillary electrophoresis capillary zone electrophoresis
Online Access:	https://www.sechenovmedj.com/jour/article/view/684

Similar Items

IS THE INCIDENCE TREND OF HEPARIN-INDUCED THROMBOCYTOPENIA DECREASED BY THE INCREASED USE OF LOW-MOLECULAR-WEIGHT-HEPARIN?
by: Fahad Al-Eidan
Published: (2015-04-01)

Influence of low molecular weight heparin on cancer patients’ survival
by: V. V. Ptushkin
Published: (2014-07-01)

Influence of low molecular weight heparin on cancer patients’ survival
by: V. V. Ptushkin
Published: (2014-07-01)

Therapeutic inefficacy of protocol driven intravenous unfractionated heparin infusion in the current era
by: Kayla Torppey, et al.
Published: (2023-10-01)

An Ovarian Cancer Patient Presenting Heparin - Induced Thrombocytopenia after use of Low - Molecular - Weight Heparin: A Case Report of Rare Condition
by: Yasin Durmuş, et al.
Published: (2019-12-01)

Comparison of Pregnancy Outcomes of Low Molecular Weight Heparin with Unfractionated Heparin in the Treatment of Recurrent Abortion Secondary to Antiphospholipid Syndrome
by: M Janghorbani, et al.
Published: (2013-09-01)

Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database
by: Leping Liu, et al.
Published: (2023-09-01)

Cost reduction associated with heparin-induced thrombocytopenia panel ordering for enoxaparin versus heparin for prophylactic and therapeutic use: A retrospective analysis in a community hospital setting
by: Harry Menon, et al.
Published: (2018-10-01)

A Comparative Study Assessing the Incidence and Degree of Hyperkalemia in Patients on Unfractionated Heparin versus Low-Molecular Weight Heparin
by: Naseralallah L, et al.
Published: (2024-12-01)

The Effects of Low Molecular Weight Heparin on Microalbuminuria in Patients with Type II Diabetes Mellitus
by: Meltem Sertbaş, et al.
Published: (2020-06-01)

Cartridge-Based Thromboelastography Can Be Used to Monitor and Quantify the Activity of Unfractionated and Low-Molecular-Weight Heparins
by: João D. Dias, et al.
Published: (2019-07-01)

Multifaceted role of heparin in oncology: from anticoagulation to anticancer mechanisms and clinical implications
by: Niranjan Koirala, et al.
Published: (2025-02-01)

Confusing combination of thrombocytopenia and thrombosis after heparin therapy in a patient with cardiac leiomyosarcoma; a nephrologist viewpoint
by: Ardalan Mohammad-Reza
Published: (2014-04-01)

A need for evidence-based clinical practice guidelines for the use of heparins in the elderly
by: Isabelle Gouin-Thibault, et al.
Published: (2010-04-01)

Heparin and its derivatives in the treatment of arterial thrombosis: a review
by: M. Dvorak, et al.
Published: (2010-11-01)

Molecular Weights of Bovine and Porcine Heparin Samples: Comparison of Chromatographic Methods and Results of a Collaborative Survey
by: Sabrina Bertini, et al.
Published: (2017-07-01)

The effect of heparins on plasma concentration of heparin-binding protein: a pilot study
by: Halla Halldorsdottir, et al.
Published: (2024-03-01)

Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
by: Baranca Buijsers, et al.
Published: (2020-09-01)

Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients
by: Mahmut Yüksel, et al.
Published: (2009-12-01)

Can We Produce Heparin/Heparan Sulfate Biomimetics Using “Mother-Nature” as the Gold Standard?
by: Brooke L. Farrugia, et al.
Published: (2015-03-01)

Low Molecular Weight Heparin Overdose: A 10 Year Case Series
by: Adeline Ngo, et al.
Published: (2013-06-01)

Heparin therapy in sepsis and sepsis-associated disseminated intravascular coagulation: a systematic review and meta-analysis
by: Takaaki Totoki, et al.
Published: (2024-09-01)

Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients
by: Pasquale Paolisso, et al.
Published: (2020-08-01)

Thromboprophylaxis in obstetrics: who, when and how
by: A V Kulikov, et al.
Published: (2014-10-01)

Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis
by: Hind Harrak Lazrak, et al.
Published: (2017-06-01)

Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital
by: A. S. Kolbin, et al.
Published: (2015-03-01)

International normalized ratio measurement during perioperative anticoagulation bridging with low-molecular-weight heparin in patients undergoing heart valve replacement surgery
by: Liza Rijvers, et al.
Published: (2024-11-01)

A Fatal Case of a Large Abdominal Wall Muscle Hematoma Secondary to Low-Molecular-Weight Heparin Injections
by: Mi Yeon Kim, et al.
Published: (2014-05-01)

Bowel obstruction from intramural hematoma in two children treated with low molecular weight heparin: Case report and review of the literature
by: Richard M. Schroeder, et al.
Published: (2014-10-01)

Assessment of the effects of low molecular heparins in pulmonary embolism prophylaxis
by: Michał Piwoński, et al.
Published: (2019-05-01)

Assessment of the effects of low molecular heparins in pulmonary embolism prophylaxis
by: Michał Piwoński, et al.
Published: (2019-05-01)

Prescriber perceptions of the safety and efficacy of unfractionated heparin versus low molecular weight heparin in the acute treatment phase: a qualitative study
by: Danielle Green, et al.
Published: (2024-12-01)

PLACE OF LOW-MOLECULAR-WEIGHT HEPARINS IN INTENSIVE THERAPY OF HEPATIC INSUFFICIENCY
by: A. N. Shmakov, et al.
Published: (2020-03-01)

Randomized, Blinded Trial Comparing Enoxaparin with Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention
by: Hosein Vakili, et al.
Published: (2007-04-01)

Randomized, Blinded Trial Comparing Enoxaparin with Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention
by: Hosein Vakili, et al.
Published: (2007-07-01)

Anticoagulant Activity of Heparins from Different Animal Sources are Driven by a Synergistic Combination of Physical-chemical Factors
by: Stephan N.M.C.G. Oliveira, et al.
Published: (2022-10-01)

Determination of the Molecular Weight of Low-Molecular-Weight Heparins by Using High-Pressure Size Exclusion Chromatography on Line with a Triple Detector Array and Conventional Methods
by: Antonella Bisio, et al.
Published: (2015-03-01)

The safety of low-molecular-weight heparins in the prevention of venous thromboembolism in surgically-treated cancer patients: results of a multicentre observational study
by: Tomasz Olesiński, et al.
Published: (2017-06-01)

Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, or both?
by: Sergio Siragusa
Published: (2011-12-01)

Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, or both?
by: Sergio Siragusa
Published: (2011-12-01)